SCHEMBL4872864

SCHEMBL4872864

C=CCOc1cccc(C(=O)OCC)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.62
ADRB1 P08588 1/20 0.62
ADRB3 P13945 1/20 0.62
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
CYP4F2 P78329 1/20 0.48
CYP4A11 Q02928 1/20 0.48
KAT6A Q92794 1/20 0.46
F2 P00734 1/20 0.46
F10 P00742 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27294341 0.90 ADRB2 (0.62) ADRB2ADRB1ADRB3ALDH1A1NPC1
SCHEMBL18705336 0.85 ADRB2 (0.51) ADRB2ADRB1ADRB3TDP1L3MBTL1
SCHEMBL9152506 0.85 TDP1 (0.56) ADRB2ADRB1ADRB3TDP1L3MBTL1
SCHEMBL758035 0.85 ADRB2 (0.61) ADRB2ADRB1ADRB3L3MBTL1ALDH1A1
SCHEMBL20762833 0.85 CYP3A4 (0.53) ALDH1A1NPC1RAB9AKMT2AKDM4E
SCHEMBL20391513 0.85 CA12 (0.50) ADRB2ADRB1ADRB3TDP1L3MBTL1
SCHEMBL1989713 0.85 KMT2A (0.62) TDP1L3MBTL1ALDH1A1NPC1RAB9A
SCHEMBL11170863 0.84 ADRB2 (0.48) ADRB2ADRB1ADRB3ALDH1A1NPC1
SCHEMBL15591254 0.82 KDM4E (0.58) ADRB2ADRB1ADRB3ALDH1A1NPC1
SCHEMBL10958710 0.82 MAPT (0.48) ADRB2ADRB1ADRB3TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236964-B2 Thiazolidine derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 US disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed
US-20100113531-A1 THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2010-05-06 US disclosed
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors NOVARTIS AG (CH) 2008-06-05 US disclosed
EP-1851208-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2007-11-07 EP disclosed
WO-2006074950-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR ADRB2 57/4885ADRB1 45/4885ADRB3 84/4885
US-20100113531-A1 THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, NPY1R ADRB2 92/4885ADRB1 72/4885ADRB3 114/4885
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R ADRB2 33/4885ADRB1 53/4885ADRB3 77/4885
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors BACE1, BACE2, APP ADRB2 840/4885ADRB1 1019/4885ADRB3 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.